Amgen says lung cancer drug combo cuts death risk 58%
By The BriefBrief
Amgen said its drug, when combined with an AstraZeneca immunotherapy, cut the risk of death by 58% in patients with an aggressive form of lung cancer. The treatment combination was assessed in a clinical trial.
WHO:Amgen
WHAT:Amgen said its drug combined with an AstraZeneca immunotherapy cut the risk of death by 58% in patients with aggressive lung cancer.
WHEN:Reported Oct 24, 2026 at 11:24 AM ET
WHERE:Location not specified
WHY:The combination was studied to assess its effect on survival in patients with aggressive lung cancer.
Reporting from 2 identified publishers across this event arc.
